Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Utilization of Ruxolitinib for Polycythemia Vera

July 7th 2020

Polycythemia Vera: Ruxolitinib Trial Data

July 7th 2020

Polycythemia Vera: Switching Therapy

July 7th 2020

Treatment Options for High-Risk Polycythemia Vera

July 7th 2020

Management of Low-Risk Polycythemia Vera

July 7th 2020

Polycythemia Vera: Monitoring Patients

July 7th 2020

Polycythemia Vera: Risk Assessment

July 7th 2020

Polycythemia Vera: Prognostic Markers

July 7th 2020

Polycythemia Vera: Bone Marrow Biopsies

July 7th 2020

Polycythemia Vera: Diagnostic Work-up

July 7th 2020

Characterization of Myeloproliferative Neoplasms

July 7th 2020

Dr. Verstovsek on Limitations of the Current Treatment Landscape of Myelofibrosis

July 1st 2020

Srdan Verstovsek, MD, PhD, discusses the limitations of the current treatment landscape of myelofibrosis.

European Commission Approves Luspatercept for Transfusion-Dependent Anemia in MDS or Beta-Thalassemia

June 26th 2020

The European Commission has approved luspatercept-aamt (Reblozyl) as a treatment for patients with transfusion-dependent anemia from very low-, low-, and intermediate-risk myelodysplastic syndromes with ring sideroblasts who had unsatisfactory response or are not candidates for erythropoietin-based therapy, and patients with transfusion-dependent anemia linked with beta thalassemia.

CPI-0610 Shows Practice-Changing Potential in Myelofibrosis

June 25th 2020

The novel BET inhibitor CPI-0610 demonstrated clinical activity with or without ruxolitinib in patients with JAK inhibitor-naïve and JAK inhibitor-exposed or -intolerant myelofibrosis.

Dr. Cortes on the Benefit of Ruxolitinib in MPNs

June 17th 2020

Jorge E. Cortes, MD, discusses the benefits of ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms.

Dr. Fleur-Lominy on Targeted Pathways in MPNs

June 15th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses targeted pathways in myeloproliferative neoplasms.

Real-World Evidence Supports Ruxolitinib Reinitiation in Myelofibrosis

June 10th 2020

Naveen Pemmaraju, MD, discusses the potential benefit of rechallenging ruxolitinib in patients with myelofibrosis.

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 9th 2020

Prithviraj Bose, MD, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Management of Patients With Myelofibrosis Who Progress on Ruxolitinib

June 8th 2020

Prithviraj Bose, MD, associate professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses management strategies for patients with myelofibrosis who progress on ruxolitinib (Jakafi).

Dr. Bose on the Utility of Ruxolitinib in Myelofibrosis

June 6th 2020

Prithviraj Bose, MD, discusses the utility of ruxolitinib in patients with myelofibrosis.